<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244228</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0016878-101</org_study_id>
    <secondary_id>2017-001385-26</secondary_id>
    <secondary_id>16-028</secondary_id>
    <nct_id>NCT03244228</nct_id>
  </id_info>
  <brief_title>A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878</brief_title>
  <official_title>A Two-part, Randomised, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of Oral HTL0016878 in Healthy Younger Adult and Elderly Subjects With a Randomised, Open-label, Crossover Arm to Assess the Effect of Food on Bioavailability of Oral HTL0016878.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, first in human, two-part, single centre, placebo-controlled, single and multiple
      ascending dose trial in healthy younger and elderly adult subjects, with an open-label,
      randomised, crossover arms to assess the effect of food on bioavailability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first in human single and multiple ascending dose study with the objective to
      evaluate safety, tolerability, PK, PD, and food effect of HTL0016878 in healthy younger and
      elderly subjects. Part 1 will assess single doses of HTL0016878 and Part 2 will assess
      multiple doses of HTL0016878. Part 1 will be divided into 3 sub-parts: Part 1a will assess
      single ascending doses (SAD) of HTL0016878 in younger adult subjects, Part 1b will evaluate
      the effect of food on bioavailability of HTL0016878 and part 1c will investigate the effect
      of age on the PK of HTL0016878. Part 1c will only proceed after review of safety,
      tolerability and PK data from part 1a. Part 2 will be divided into 2 sub-parts to assess
      multiple ascending doses (MAD) of HTL0016878 in younger adult (part 2a) and elderly adult
      (part 2b) subjects. Part 2 will only proceed after review of safety, tolerability and PK data
      from Parts 1a, b and c.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs (Heart Rate and Blood pressure)</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory safety assessment</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia- suicide severity rating scale (C-SSRS)</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum plasma concentration (Tmax) of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted in urine (Ae) of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose eliminated unchanged on urine (fe/F) of HTL0016878</measure>
    <time_frame>Baseline up to 14 days post dose</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1a SAD HTL0016878/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b single dose HTL0016878</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c single dose HTL0016878</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a MAD HTL0016878/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b MAD HTL0016878/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0016878</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Part 1a SAD HTL0016878/Placebo</arm_group_label>
    <arm_group_label>Part 1b single dose HTL0016878</arm_group_label>
    <arm_group_label>Part 1c single dose HTL0016878</arm_group_label>
    <arm_group_label>Part 2a MAD HTL0016878/Placebo</arm_group_label>
    <arm_group_label>Part 2b MAD HTL0016878/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Part 1a SAD HTL0016878/Placebo</arm_group_label>
    <arm_group_label>Part 2a MAD HTL0016878/Placebo</arm_group_label>
    <arm_group_label>Part 2b MAD HTL0016878/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normotensive 18-55 year old (Parts 1a, 1b and 2a only) or 65+ year old (Parts 1c and
             2b) male (all parts) or female (parts 1b, 2a and 2b only) volunteers with a body mass
             index 18-32kg/mÂ².

          -  Healthy on the basis of a clinical history, physical examination, electrocardiogram
             (ECG), vital signs, heart rate (part 1a only), exercise history (part 1a only), and
             laboratory tests of blood and urine.

          -  Willingness to comply with requirements or the trial, including contraception
             requirements.

          -  Able to give fully informed consent.

        Exclusion Criteria:

          -  Positive tests for hepatitis B &amp; C, HIV

          -  severe adverse reaction to any drug

          -  sensitivity to trial medication

          -  drug or alcohol abuse

          -  smoking

          -  use of medication that inhibits CYP2D6 within previous 21 days or other prescribed and
             over-the-counter medication and herbal remedies within previous 21 days before dosing
             (with the exception of acetaminophen, contraceptive medications and hormone
             replacement therapy), unless the principal investigator (PI) considers that it would
             not interfere with trial

          -  participation in other clinical trials of unlicensed medicines in the previous 3
             months, or regularly take part in more than 4 studies a year

          -  loss of more than 500 mL blood in the previous 3 months

          -  vital signs, QTcF interval or laboratory values outside the acceptable range

          -  poor metabolizers of CYP2D6 (apart from one optional cohort in Part 1a, which may
             enrol poor metabolizers only)

          -  clinically relevant abnormal findings at the screening assessment

          -  acute or chronic illness

          -  history of epilepsy or seizures

          -  clinically relevant abnormal medical history or concurrent medical condition

          -  disease associated with cognitive impairment and/or psychosis

          -  recent history of suicidal thoughts or ideation, or insomnia

          -  excessive use of caffeine containing beverages, exceeding 8 cups of coffee or
             equivalent/day and the inability to refrain from the use of caffeine containing
             beverages whilst on the ward

          -  consumption of cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus
             fruits or Seville oranges (including marmalade and juices made from these fruits)
             within 3 days before admission; possibility that volunteer will not cooperate

          -  pre-menopausal females who are pregnant or lactating, or who are sexually active and
             not using a reliable method of contraception

          -  Objection by the GP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malcolm Boyce, BSc MD FRCP FFPM</last_name>
    <phone>020 8961 4130</phone>
    <email>mboyce@hmrlondon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <state>Hammersmith</state>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Boyce, BSc MD FRCP FFPM</last_name>
      <phone>020 8961 4130</phone>
      <email>mboyce@hmrlondon.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in human</keyword>
  <keyword>Multiple ascending dose</keyword>
  <keyword>Single ascending dose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

